Drug intelligence / Profile preview

escitalopram + trazodone

Development stage
Unknown
Lead developer
Lundbeck
Modality
Small Molecules
Administration
Oral
01

Overview

Escitalopram + trazodone is a combination of two antidepressant medications, each with distinct mechanisms of action. Escitalopram is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin levels in the brain by inhibiting its reuptake, primarily used to treat depression and anxiety disorders. Trazodone is classified as a serotonin antagonist and reuptake inhibitor (SARI); it acts by both inhibiting the reuptake of serotonin and antagonizing certain serotonin receptors, making it effective for major depressive disorder and commonly used off-label for insomnia due to its sedative properties. The concurrent use of these drugs can be considered in patients with comorbid mood disorders and sleep disturbances but carries significant risks, most notably an increased risk of serotonin syndrome—a potentially life-threatening condition caused by excessive serotonergic activity—as well as additive sedative effects leading to central nervous system depression, impaired coordination, orthostatic hypotension, QT prolongation (heart rhythm disturbances), sexual dysfunction, and exacerbation of other side effects such as dizziness or dry mouth[1][2][3][4][5]. This combination should only be prescribed under close medical supervision.

Other names
lexapro + trazodone
02

Targets

ADRA1A (α1A)SERT (Sodium-dependent serotonin transporter)HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)

Beyond the preview

Go deeper on escitalopram + trazodone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on escitalopram + trazodone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call